Please login to the form below

Not currently logged in
Email:
Password:

CGRP antagonists

This page shows the latest CGRP antagonists news and features for those working in and with pharma, biotech and healthcare.

Teva buys into Heptares oral CGRP programme for migraine

Teva buys into Heptares oral CGRP programme for migraine

The agreement - which includes a $10m upfront payment from Teva to Heptares - covers a series of small-molecule calcitonin gene-related peptide (CGRP) antagonists, all of which are currently in preclinical ... CGRP is a neurotransmitter that is elevated

Latest news

  • Allergan stumps up $375m for bolt-on acquisitions Allergan stumps up $375m for bolt-on acquisitions

    The deal with Merck covers MK-1602 and MK-8031, both of which are orally active, small molecule CGRP antagonists for the acute treatment of migraines. ... They are in a race to market with other CGRP antagonists such as Teva's TEV-48125 - which is also

  • Migraine drugs' headache Migraine drugs' headache

    CGRP can also cause the release of inflammatory agents from meningeal mast cells. ... It is thought that CGRP receptor antagonists could alleviate migraine symptoms by blocking these pathophysiological activities of CGRP.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics